Tigris Pharmaceuticals
Biopharmaceutical developer of therapeutic technologies for oncology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
$6.5m | Series C | ||
| Total Funding | 000k | ||
Tigris Pharmaceuticals, Inc., also known as Kirax Corporation, was a biopharmaceutical company founded in 2005 and based in Bonita Springs, Florida. The company focused on developing therapeutic technologies to address unmet medical needs, primarily in the field of oncology.
The company's drug development pipeline included several compounds. Its lead molecule was AFP-464 (aminoflavone 464), an anticancer agent that targets the aryl hydrocarbon receptor (AhR). This drug was in development for treating various cancers, including triple-negative breast cancer, pancreatic, ovarian, and renal cell cancers. Other notable compounds in its pipeline were GGTI-2418, a geranylgeranyltransferase inhibitor for solid tumors, and GFB-204, a growth factor binding selective inhibitor targeting VEGFR and PDGFR, also for solid tumors.
Throughout its operation, Tigris Pharmaceuticals raised a total of $32.5 million in funding over three rounds. The initial funding round occurred in October 2005, and the last was a Series C round on September 29, 2010, which raised $6.5 million and was led by Neil Flanzraich. Key institutional investors included Sonostar Ventures, Wexford Capital, and NGN Capital. In 2009, Edmundo Muniz, MD, PhD, served as the President and CEO, and Pedro Granadillo was appointed Chairman of the Board. In 2010, Neil Flanzraich was appointed Executive Chairman of the Board. The company is now considered deadpooled.
Keywords: biopharmaceutical, oncology therapeutics, cancer treatment, drug development, AFP-464, aminoflavone, triple negative breast cancer, pancreatic cancer, ovarian cancer, renal cell cancer, GGTI-2418, GFB-204, solid tumors, aryl hydrocarbon receptor, clinical trials, venture capital